Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
The Evolution of Immuno-Oncology (I-O) Therapies Across the Urothelial Carcinoma Treatment Landscape
Recorded Live From AUA2024
About the Webinar
Treatment options in muscle invasive urothelial carcinoma (MIUC) and metastatic urothelial carcinoma (mUC) have evolved in recent years. This non-CME webinar will focus on:
- The scientific rationale to support adjuvant immunotherapy given in MIUC with a high-risk of recurrence after radical resection, presented by a urology expert
- The scientific rationale to support immunotherapy given concurrently with chemotherapy as a first-line treatment option in mUC, presented by a medical oncologist
- The importance of communication and collaboration across the multidisciplinary team, the central role of the urologist, and how they can help to manage patients on immunotherapy will be discussed.
Speakers
Karim Chamie, MD
Ulka Vaishampayan, MD